193 related articles for article (PubMed ID: 38632022)
1. Complete response to front-line therapies is associated with long-term survival in HIV-related lymphomas in Taiwan.
Ma WL; Liu WD; Sun HY; Sheng WH; Hsieh SM; Wu SJ; Hung CC
J Microbiol Immunol Infect; 2024 Jun; 57(3):426-436. PubMed ID: 38632022
[TBL] [Abstract][Full Text] [Related]
2. HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy.
Castelli R; Schiavon R; Preti C; Ferraris L
Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):175-180. PubMed ID: 32294049
[TBL] [Abstract][Full Text] [Related]
3. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.
Gopal S; Patel MR; Yanik EL; Cole SR; Achenbach CJ; Napravnik S; Burkholder GA; Reid EG; Rodriguez B; Deeks SG; Mayer KH; Moore RD; Kitahata MM; Eron JJ; Richards KL
J Natl Cancer Inst; 2013 Aug; 105(16):1221-9. PubMed ID: 23892362
[TBL] [Abstract][Full Text] [Related]
4. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Barta SK; Samuel MS; Xue X; Wang D; Lee JY; Mounier N; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Little RF; Dunleavy K; Wilson WH; Wyen C; Remick SC; Kaplan LD; Ratner L; Noy A; Sparano JA
Ann Oncol; 2015 May; 26(5):958-966. PubMed ID: 25632071
[TBL] [Abstract][Full Text] [Related]
5. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K; Ramaswami R; Mangusan R; Widell A; Ekwede I; George J; Ambinder R; Cheever M; Gulley JL; Goncalves PH; Wang HW; Uldrick TS; Yarchoan R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608378
[TBL] [Abstract][Full Text] [Related]
6. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Barta SK; Xue X; Wang D; Tamari R; Lee JY; Mounier N; Kaplan LD; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Wilson WH; Wyen C; Oriol A; Navarro JT; Dunleavy K; Little RF; Ratner L; Garcia O; Morgades M; Remick SC; Noy A; Sparano JA
Blood; 2013 Nov; 122(19):3251-62. PubMed ID: 24014242
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
de Witt P; Maartens DJ; Uldrick TS; Sissolak G
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):66-73. PubMed ID: 23797692
[TBL] [Abstract][Full Text] [Related]
8. Malignant lymphoma in the HIV-positive patient.
Meister A; Hentrich M; Wyen C; Hübel K
Eur J Haematol; 2018 Jul; 101(1):119-126. PubMed ID: 29663523
[TBL] [Abstract][Full Text] [Related]
9. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Ramos JC; Sparano JA; Chadburn A; Reid EG; Ambinder RF; Siegel ER; Moore PC; Rubinstein PG; Durand CM; Cesarman E; Aboulafia D; Baiocchi R; Ratner L; Kaplan L; Capoferri AA; Lee JY; Mitsuyasu R; Noy A
Blood; 2020 Sep; 136(11):1284-1297. PubMed ID: 32430507
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
11. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
Baptista MJ; Garcia O; Morgades M; Gonzalez-Barca E; Miralles P; Lopez-Guillermo A; Abella E; Moreno M; Sancho JM; Feliu E; Ribera JM; Navarro JT
AIDS; 2015 Apr; 29(7):811-8. PubMed ID: 25730510
[TBL] [Abstract][Full Text] [Related]
12. HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
Sharma A; Bajpai J; Raina V; Mohanti BK
Indian J Cancer; 2010; 47(1):35-9. PubMed ID: 20071788
[TBL] [Abstract][Full Text] [Related]
13. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.
; Bohlius J; Schmidlin K; Costagliola D; Fätkenheuer G; May M; Caro Murillo AM; Mocroft A; Bonnet F; Clifford G; Touloumi G; Miro JM; Chene G; Lundgren J; Egger M
AIDS; 2009 Sep; 23(15):2029-37. PubMed ID: 19531926
[TBL] [Abstract][Full Text] [Related]
15. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
18. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy.
Han X; Jemal A; Hulland E; Simard EP; Nastoupil L; Ward E; Flowers CR
Cancer Epidemiol Biomarkers Prev; 2017 Mar; 26(3):303-311. PubMed ID: 27756777
[No Abstract] [Full Text] [Related]
19. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers P; Gillor D; Hentrich M; Wyen C; Wolf T; Oette M; Zoufaly A; Wasmuth JC; Bogner JR; Müller M; Esser S; Schleicher A; Jensen B; Stoehr A; Behrens G; Schultze A; Siehl J; Thoden J; Taylor N; Hoffmann C
Haematologica; 2018 May; 103(5):857-864. PubMed ID: 29439188
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]